ArticleFrontiers in public health2025
Disease burden and trends of malignant neoplasm of bone and articular cartilage in childhood in China, 1990-2021 and comparison with United States and India: findings from the Global Burden of Disease Study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessment of the Burden of Maternal Hypertensive Disorders and the Quality of Care in China: A Systematic Analysis of the Global Burden of Disease (GBD) 2021 Study.International journal of women's health · 2026Article
- Global burden and forecast of malignant neoplasms of bone and articular cartilage from 1990 to 2030.Frontiers in medicine · 2025Article
- Trends, Global Comparisons, and Projections of the Burden of Malignant Neoplasm of Bone and Articular Cartilage in China Based on GBD 2021.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to analyze the disease burden and trends of malignant neoplasm of bone and articular cartilage (MNBAC) in Chinese children from 1990 to 2021 using data from GBD 2021, and to compare them with the United States and India. Methods: Data on incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for MNBAC in children aged 0-14 years were extracted from GBD 2021. The joinpoint regression analysis model was employed to assess temporal trends, and the average annual percent change (AAPC) was calculated to summarize the trends over the study period. Results: Globally, the number of incident childhood cases of MNBAC increased from 9,827 in 1990 to 12,294 in 2021, with an AAPC of 0.38. Similarly, the prevalence of the disease also increased, with an AAPC of 0.39. However, the mortality rate and DALYs rate showed a slight decline, with an AAPC of -0.16 and -0.16 respectively. At the national level, the United States had the highest incidence and prevalence rates, while India had the highest number of incident cases and DALYs. China showed the largest increase in prevalence, with an AAPC of 1.88. India also demonstrated the most significant decline in mortality and DALYs rates. Additionally, the mortality rate and DALYs rate were slightly higher for male children compared to female patients. Conclusion: Malignant bone and articular cartilage tumors in children remain a significant public health challenge globally. By strengthening monitoring, increasing investment in medical resources, promoting early screening and intervention, and enhancing international cooperation and exchange, we hope to further reduce the burden of childhood bone cancer and improve children's quality of life and health standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.